Mar 12 2021 Read 412 Times
In a recent study led by MedUni Vienna and the University of Vienna, researchers demonstrated that dimerized (a combination of two identical or different molecules) and therefore significantly larger versions of human neuropeptides oxytocin and vasopressin are still able to activate their receptors without forfeiting too much of their efficacy. Such new constructs provide several opportunities to optimise the efficacy of these neuropeptides for therapeutic application.
Oxytocin/vasopressin receptors are typical examples of so-called G protein-coupled receptors – the most successful drug target class, which are being investigated for therapeutic applications in cardiovascular disease, cancer and developmental disorders such as autism.
Scientists present new outlook on latest trends in peptide drug discovery and development
Currently there are more than 80 peptide drugs on the global market and about twice as many in clinical development. Due to their beneficial properties, these biomolecules play already an important role in the treatment of diseases such as diabetes, cancer, hormone disorders, HIV infection, and multiple sclerosis.
In the recent issue of
Nature Reviews Drug Discovery , a team of Austrian and Australian scientists led by medicinal chemist Markus Muttenthaler of the University of Vienna present an outlook on the latest trends in peptide drug discovery and development.
There are more than 80 peptide drugs on the global market and about twice as many in clinical development. Due to their beneficial properties, these biomolecules play already an important role in the treatment of diseases. In
Date Time
Therapeutic potential of peptides
Currently there are more than 80 peptide drugs on the global market and about twice as many in clinical development. Due to their beneficial properties, these biomolecules play already an important role in the treatment of diseases such as diabetes, cancer, hormone disorders, HIV infection, and multiple sclerosis. In the recent issue of “Nature Reviews Drug Discovery”, a team of Austrian and Australian scientists led by medicinal chemist Markus Muttenthaler of the University of Vienna present an outlook on the latest trends in peptide drug discovery and development.
“Insulin is a prime example for a successful peptide drug that has been essential for the health of millions of diabetic patients in the past 100 years,” says Markus Muttenthaler, who leads research groups at the Institute of Biological Chemistry of the Faculty of Chemistry at University in Vienna as well as at the Institute for Molecular Bioscience, at the University